Ferrokinetics in patients on CAPD: influence of CAPD on the anemia of uremia

CAPD患者的铁代谢动力学:CAPD对尿毒症贫血的影响

阅读:1

Abstract

Ferrokinetic studies were performed with (59)Fe-citrate to evaluate erythropoietic activity in CAPD patients and to investigate the mechanism(s) by which the hematocrit increases in CAPD patients. Plasma iron disappearance rate (PID), plasma iron turnover rate (PIT), red cell iron utilization (RCIU), red cell iron turnover rate (RCIT) and marrow transit time (MTT) were all “normal” in uremic patients not yet on dialysis (Hct 23.8±3.4%), CAPD patients with persistently low hematocrit (Hct 24.9±1.8%) and CAPD patients with improved hematocrit (Hct 32.4±3.1%). Compared to these uremic patients, patients with iron deficiency anemia and normal renal function (Hct 28.0±5.1 %) had significantly faster PID and MTT and significantly higher RCIU and RCIT. Plasma volume was significantly reduced (to normal level) in CAPD patients with improved hematocrits. The results of this study suggest that erythropoietic activity is inadequate for the degree of anemia in CAPD patients as well as uremic patients not on dialysis and further suggest that the hematocrit increases in CAPD as a result of decreased plasma volume.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。